TherapeuticsMD (TXMD) 10-K 5 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 03, 2014	Jun. 28, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'TherapeuticsMD, Inc.	'	'
Entity Central Index Key	'0000025743	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$278,462,272
Entity Common Stock, Shares Outstanding	'	145,017,060	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash	$54,191,260	$1,553,474
Accounts receivable, net of allowance for doubtful accounts of $26,555 and $42,048, respectively	1,690,753	714,425
Inventory	1,043,618	1,615,210
Other current assets	2,477,715	751,938
Total current assets	59,403,346	4,635,047
Fixed assets, net	61,318	65,673
Other Assets:	'	'
Prepaid expense	1,750,455	953,655
Intangible assets	665,588	239,555
Security deposit	135,686	31,949
Total other assets	2,551,729	1,225,159
Total assets	62,016,393	5,925,879
Current Liabilities:	'	'
Accounts payable	2,114,217	1,641,366
Deferred revenue	1,602,580	1,144,752
Other current liabilities	3,601,189	833,654
Total current liabilities	7,317,986	3,619,772
Long-Term Liabilities:	'	'
Notes payable, net of debt discount of $0 and $1,102,680, respectively	'	3,589,167
Accrued Interest	'	150,068
Total Long-term liabilities	'	3,739,235
Total liabilities	7,317,986	7,359,007
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding	'	'
Common stock - par value $0.001; 250,000,000 shares authorized; 144,976,757 and 99,784,982 issued and outstanding, respectively	144,977	99,785
Additional paid in capital	135,086,056	50,580,400
Accumulated deficit	-80,532,626	-52,113,313
Total stockholders' equity	54,698,407	-1,433,128
Total liabilities and stockholders' equity	$62,016,393	$5,925,879

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts	$26,555	$42,048
Debt discount on notes payable	$0	$1,102,680
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	144,976,757	99,784,982
Common stock, shares outstanding	144,976,757	99,784,982

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Revenues, net	$8,775,598	$3,818,013	$2,088,177
Cost of goods sold	1,959,597	1,348,113	947,112
Gross profit	6,816,001	2,469,900	1,141,065
Operating expenses:	'	'	'
Sales, general, and administrative	19,014,837	14,069,701	6,406,197
Research and development	13,551,263	4,492,362	107,241
Depreciation and amortization	58,145	56,260	54,845
Total operating expense	32,624,245	18,618,323	6,568,283
Operating loss	-25,808,244	-16,148,423	-5,427,218
Other income and (expense)	'	'	'
Miscellaneous income	34,544	3,001	6,392
Interest income	27,234	'	'
Financing costs	-1,503,922	'	'
Interest expense	-1,165,981	-1,905,409	-64,380
Loan guaranty costs	-2,944	-45,036	-38,159
Loss on extinguishment of debt	'	-10,307,864	-7,390,000
Beneficial conversion feature	'	-6,716,504	'
Total other income (expense)	-2,611,069	-18,971,812	-7,486,147
Loss before taxes	-28,419,313	-35,120,235	-12,913,365
Net loss	($28,419,313)	($35,120,235)	($12,913,365)
Net loss per share, basic and diluted	($0.22)	($0.38)	($0.21)
Weighted average number of shares outstanding	127,569,731	91,630,693	62,516,461

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2010	$55,487	$4,988,637	($4,079,713)	$964,411
Beginning balance, shares at Dec. 31, 2010	55,487,321	'	'	'
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement	166	-255,919	'	-255,753
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement, shares	165,879	'	'	'
Shares issued in private placement, net of cost	5,552	1,701,448	'	1,707,000
Shares issued in private placement, net of cost, shares	5,551,589	'	'	'
Shares issued in exchange for debt	21,682	8,217,455	'	8,239,137
Shares issued in exchange for debt, shares	21,681,958	'	'	'
Shares issued for exercise of options	92	17,158	'	17,250
Shares issued for exercise of options, shares	92,057	'	'	'
Options issued as compensation	'	183,355	'	183,355
Warrants issued for services	'	190,280	'	190,280
Warrants issued for loan guaranty costs-related parties	'	93,969	'	93,969
Warrants issued for financing costs	'	45,362	'	45,362
Warrants issued as financing costs-related parties	'	9,338	'	9,338
Warrants issued as compensation-related party	'	7,158	'	7,158
Net loss	'	'	-12,913,365	-12,913,365
Ending balance at Dec. 31, 2011	82,979	15,198,241	-16,993,078	-1,711,858
Ending balance, shares at Dec. 31, 2011	82,978,804	'	'	'
Shares issued in private placement, net of cost	3,954	7,891,531	'	7,895,485
Shares issued in private placement, net of cost, shares	3,953,489	'	'	'
Shares issued in exchange for debt	2,775	1,051,882	'	1,054,657
Shares issued in exchange for debt, shares	2,775,415	'	'	'
Shares issued for exercise of options	1,932	189,068	'	191,000
Shares issued for exercise of options, shares	1,931,788	'	'	'
Shares issued in exercise of warrants	8,145	3,093,855	'	3,102,000
Shares issued in exercise of warrants, shares	8,145,486	'	'	'
Options issued as compensation	'	1,832,061	'	1,832,061
Warrants issued for services	'	1,563,620	'	1,563,620
Warrants issued for financing costs	'	13,014,784	'	13,014,784
Warrants issued as compensation-related party	'	36,284	'	36,284
Warrants issued for cash	'	400	'	400
Cancellation of warrants issued for loan guaranty costs-related parties	'	-7,830	'	-7,830
Beneficial conversion feature	'	6,716,504	'	6,716,504
Net loss	'	'	-35,120,235	-35,120,235
Ending balance at Dec. 31, 2012	99,785	50,580,400	-52,113,313	-1,433,128
Ending balance, shares at Dec. 31, 2012	99,784,982	'	'	99,784,982
Shares issued in private placement, net of cost	45,117	78,605,236	'	78,650,353
Shares issued in private placement, net of cost, shares	45,116,352	'	'	'
Shares issued for exercise of options	75	30,835	'	30,910
Shares issued for exercise of options, shares	75,423	'	'	'
Warrants issued for services	'	867,262	'	867,262
Employee Share Based Compensation	'	3,254,083	'	3,254,083
Warrants issued for financing costs	'	1,711,956	'	1,711,956
Warrants issued as compensation-related party	'	36,284	'	36,284
Net loss	'	'	-28,419,313	-28,419,313
Ending balance at Dec. 31, 2013	$144,977	$135,086,056	($80,532,626)	$54,698,407
Ending balance, shares at Dec. 31, 2013	144,976,757	'	'	144,976,757

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Cash Flows [Abstract]	'	'	'
Net loss	($28,419,313)	($35,120,235)	($12,913,365)
Adjustments to reconcile net loss to net cash flows used in operating activities:	'	'	'
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement	'	'	-255,753
Depreciation	47,883	27,484	25,686
Amortization of intangible assets	10,262	28,776	29,159
Provision for doubtful accounts	-15,493	40,548	1,500
Loss on debt extinguishment	'	10,307,864	7,390,000
Beneficial conversion feature	'	6,716,504	'
Amortization of debt discount	1,102,680	1,604,240	28,719
Stock based compensation	3,207,238	1,868,345	190,513
Amortization of deferred financing costs	1,451,934	'	25,980
Stock based expense for services	636,917	338,457	22,630
Loan guaranty costs	2,944	45,036	38,159
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-1,068,619	-728,253	-16,409
Inventory	571,592	-1,027,137	29,996
Other current assets	-1,386,319	42,281	-346,822
Other assets	-565,706	'	'
Accounts payable	472,851	1,334,855	188,876
Deferred revenue	457,828	1,144,752	'
Accrued expenses and other current liabilities	2,875,320	639,157	594,535
Other liabilities	-150,068	'	'
Net cash flows used in operating activities	-20,768,069	-12,737,326	-4,966,596
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Patent costs, net of abandoned costs	-439,034	-206,101	-8,870
Payment of security deposit	-103,737	'	'
Purchase of property and equipment	-40,790	-66,405	-28,766
Net cash flows used in investing activities	-583,561	-272,506	-37,636
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from sale of common stock, net of costs	78,650,353	7,895,485	1,000,000
Proceeds bank line of credit	500,000	'	300,000
Proceeds from exercise of options	30,910	191,000	17,250
Proceeds from notes and loans payable	'	8,700,000	2,684,160
Proceeds from sale of warrants	'	400	'
Proceeds from notes and loans payable-related parties	'	'	300,000
Proceeds from sale of membership units, net of expenses	'	'	707,000
Repayment of bank line of credit	-500,000	-300,000	'
Repayment of notes payable - related party	'	-200,000	-100,696
Repayment of notes payable	-4,691,847	-1,850,000	-200,000
Net cash flows provided by financing activities	73,989,416	14,436,885	4,707,714
Increase in cash	52,637,786	1,427,053	-296,518
Cash, beginning of period	1,553,474	126,421	422,939
Cash, end of period	54,191,260	1,553,474	126,421
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	'	'	'
Cash paid for interest	212,853	17,253	696
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:	'	'	'
Warrants issued for financing	1,711,956	2,509,537	148,668
Warrants issued for services	462,196	1,532,228	190,280
Warrants exercised in exchange for debt and accrued interest	'	3,102,000	'
Shares issued in exchange for debt and accrued interest	'	1,054,658	849,137
Notes payable issued for accrued interest	'	$15,123	'

THE_COMPANY

THE COMPANY	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
THE COMPANY	'
	NOTE 1 – THE COMPANY
	TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”
	Nature of Business
	We are a women’s healthcare product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of providing equivalent efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture (through third parties) and distribute branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and cosmetics.
	Agreement and Plan of Merger with VitaMed
	On July 18, 2011, we entered into an Agreement and Plan of Merger with VitaMed and our newly formed wholly owned subsidiary. In connection with the acquisition, our subsidiary merged with and into VitaMed with VitaMed surviving the merger. The merger became effective upon the filing of the Certificate of Merger with the Secretary of State of the State of Delaware on October 4, 2011. In preparation for and prior to the closing of the Merger, we completed the following required corporate actions:
		·	a reverse split of our 16,575,209 issued and outstanding shares of our common stock, par value $0.001 per share, or the Common Stock, on a ratio of 1-for-100. As a result of the reverse split, each share of Common Stock outstanding on the July 28, 2011 record date, without any action on the part of the holder thereof, became one one-hundredth of a share of Common Stock. The reverse split decreased the number of outstanding shares of our Common Stock by approximately 99%, resulting in 165,856 shares outstanding after the reverse split. The effectuation of the reverse split did not result in a change in the relative equity position or voting power of our shareholders;
		·	an increase in the number of shares of our Common Stock authorized for issuance to 250,000,000;
		·	a change in the name of our company to TherapeuticsMD, Inc.; and
		·	an amendment to our 2009 Long Term Incentive Compensation Plan to increase the number of shares of our Common Stock reserved for issuance thereunder to 25,000,000.
	On the effective date of the merger, we acquired 100% of VitaMed in exchange for shares of our Common Stock.
	Exchange of Securities
	On the effective date of the merger, all outstanding membership units of VitaMed were exchanged for shares of our Common Stock. In addition, all outstanding options and warrants to purchase VitaMed membership units were exchanged for and converted into options and warrants to purchase shares of our Common Stock. Pursuant to the conversion ratio in the merger, we issued 58,407,331 shares of our Common Stock in exchange for the outstanding VitaMed membership units, reserved an aggregate of 10,119,796 shares of our Common Stock for issuance upon the exercise of the VitaMed options, and reserved an aggregate of 1,472,916 shares of our Common Stock for issuance upon the exercise of the warrants. After giving effect to the reverse split, and taking into consideration the 58,407,331 shares issued in exchange for the membership units, the number of shares of our Common Stock issued and outstanding as of the effective date of the merger was 58,573,187, of which the former members of VitaMed owned approximately 99%. All shares of our Common Stock issued in exchange for the VitaMed membership units and issuable upon exercise of the options and warrants were subject to a lock-up agreement for a period of 18 months from the effective date of the merger, and on a limited basis for 12 months thereafter.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances and transactions have been eliminated in consolidation.
	Cash
	We maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured limits.
	Trade Accounts Receivable and Allowance for Doubtful Accounts
	Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance for doubtful accounts when received. To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required.
	Inventories
	Inventories represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time as the related deferred revenue is recognized.
	Fixed Assets
	Equipment
	We state equipment at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expense as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years.
	Leasehold Improvements
	We state improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining term of the lease.
	Intangible Assets
	Patent and Trademarks
	We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, Intangible-Goodwill and Other, or ASC 350. Capitalized patent costs, net of accumulated amortization, include legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted in the year ended December 31, 2013.
	Impairment of Long-Lived Assets
	We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:
		·	significant declines in an asset’s market price;
		·	significant deterioration in an asset’s physical condition;
		·	significant changes in the nature or extent of an asset’s use or operation;
		·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying value. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.
	Fair Value of Financial Instruments
	Our financial instruments consist primarily of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which would be considered Level 3 inputs under the fair value hierarchy.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, Fair Value Measurements and Disclosures. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).
	Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At December 31, 2013, 2012, and 2011, we had no assets or liabilities that were valued at fair value on a recurring basis.
	Income Taxes
	With the advent of the Merger, we determined that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.
	We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.
	In accordance with ASC 740, Income Taxes, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.
	We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating to open tax returns that were considered to be uncertain.
	Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.
	Share-Based Compensation
	In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of the award.
	Equity instruments (“instruments”) issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC 505, Equity Based Payments to Non-Employees, or ASC 505, defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.
	We recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period.
	Debt Discounts
	Costs incurred from parties that are providing long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the related debt using the effective interest rate method.
	Revenue Recognition
	We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.
	Over-the-Counter Products
	We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.
	Prescription Products
	We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and rebates.
	We accept returns of unsalable product from customers within a return period of six months prior to and following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return.
	We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.
	Shipping and Handling Costs
	We expense all shipping and handling costs as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.
	Advertising Costs
	We expense advertising costs when incurred. Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31, 2012, respectively.
	Research and Development Expenses
	Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future R&D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.
	Earnings Per Share
	We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these periods because their effect would have been anti-dilutive due to the net loss reported by us.
Use of Estimates
Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.
Recently Issued Accounting Pronouncements
In July, 2013, the FASB issued Accounting Standards Update, or ASU, No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial statements.
In July 2012, the FASB issued ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 gives entities an option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.
In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our financial position or results of operations.
We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.
Reclassifications
Certain 2012 amounts have been reclassified to conform to current year presentation.

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2013
InventoryAbstract	'
INVENTORY	'
	NOTE 3 – INVENTORY
	Inventory consists of the following:
		December 31,
		2013		2012
	Finished product	$	621,679	$	1,124,739
	Raw material		250,943		380,000
	Deferred costs		170,996		110,471
	TOTAL INVENTORY	$	1,043,618	$	1,615,210

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2013
Other Assets:	'
OTHER CURRENT ASSETS	'
	NOTE 4 – OTHER CURRENT ASSETS
	Other current assets consist of the following:
		December 31,
		2013		2012
	Prepaid R&D costs	$	1,267,588	$	189,375
	Prepaid consulting		530,596		432,216
	Deferred financing costs		260,022		─
	Other receivable – related party		249,981		─
	Prepaid other		169,528		127,403
	Prepaid guaranty costs		─		2,944
	TOTAL OTHER CURRENT ASSETS	$	2,477,715	$	751,938

FIXED_ASSETS

FIXED ASSETS	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
FIXED ASSETS	'
	NOTE 5 – FIXED ASSETS
	Fixed assets consist of the following:
		December 31,
		2013			2012
	Equipment	$	108,458		$	67,668
	Furniture and fixtures		46,625			46,625
	Leasehold improvements		─			11,980
			155,083			126,273
	Accumulated depreciation		(93,765	)		(60,600	)
	TOTAL FIXED ASSETS	$	61,318		$	65,673
	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $45,145, $27,484 and $25,686, respectively. In December 2013, accumulated depreciation was reduced by $11,980 associated with leasehold improvements of our previously leased office property.

PREPAID_EXPENSE

PREPAID EXPENSE	12 Months Ended
	Dec. 31, 2013
Prepaid Expense, Current [Abstract]	'
PREPAID EXPENSE	'
	NOTE 6 –PREPAID EXPENSE
	Prepaid expense consists of the following:
		December 31,
		2013		2012
	Prepaid R & D costs	$	824,221	$	953,655
	Prepaid manufacturing costs		899,000		─
	Accreted prepaid costs		27,234		─
	TOTAL PREPAID EXPENSE	$	1,750,455	$	953,655

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE 7 – INTANGIBLE ASSETS
	The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2013 and December 31, 2012:
		December 31, 2013
		Gross		Accumulated			Net		Weighted-
		Carrying		Amortization			Amount		Average
		Amount							Amortization
									Period (yrs.)
	Amortizing intangible assets:
	OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
	Development costs for corporate website		91,743		(89,661	)		2,082		0.3
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents		572,726		—			572,726		n/a
	Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
	Total	$	755,748	$	(90,160	)	$	665,588
		December 31, 2012
		Gross		Accumulated			Net		Weighted-
		Carrying		Amortization			Amount		Average
		Amount							Amortization
									Period (yrs.)
	Amortizing intangible assets:
	OPERA ® software patent	$	23,722	$	0		$	23,722		0
	Development costs for corporate website		91,743		(77,159	)		14,584		1.3
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents		180,194		—			180,194		n/a
	Multiple trademarks for vitamins/supplements		21,055		—			21,055		n/a
	Total	$	316,714	$	(77,159	)	$	239,555
	The intangible asset related to development costs for corporate website is amortized over 36 months, which is the prescribed life for software and website development costs. The intangible asset related to OPERA® is amortized using the straight-line method over the estimated remaining useful life of 16 years, which is the life of the intellectual property patents.  During the year ended December 31, 2013, there was no impairment recognized.
	Amortization expense was $13,001, $28,776, $29,159 for the years ended December 31, 2013, 2012, and 2011, respectively. Estimated amortization expense for the next five years is as follows:
	Year Ending December 31,	Estimated Amortization
	2014	$	4,080
	2015		1,997
	2016		1,997
	2017		1,997
	2018		1,997

OTHER_CURRENT_LIABILITIES

OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2013
Other Liabilities, Current [Abstract]	'
OTHER CURRENT LIABILITIES	'
	NOTE 8 – OTHER CURRENT LIABILITIES
	Other current liabilities consist of the following:
		December 31,
		2013		2012
	Accrued payroll and commission costs	$	941,313	$	397,210
	Accrued financing costs		850,000		─
	Accrued vacation		256,920		114,899
	Allowance for wholesale distributor fees		306,303		107,784
	Accrued legal and accounting expense		224,550		90,000
	Accrued lab research		536,574		─
	Accrued clinical trial costs		129,208		─
	Allowance for coupons and returns		126,233		53,002
	Other accrued expenses(1)		230,088		70,759
	TOTAL OTHER CURRENT LIABILITIES	$	3,601,189	$	833,654
	(1) In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	NOTE 9 – NOTES PAYABLE
	Issuance and Payment of Multiple Advance Revolving Credit Note
	On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request, which advances were of a revolving nature and were able to be,made, repaid, and made from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid $401,085, including accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price $3.20 per share (see NOTE 10 for more details).
	Borrowing under Business Loan Agreement and Promissory Note, as amended
	In March 2011, VitaMed entered into a business loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company. The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012. We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013. On November 13, 2012, the outstanding balance of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. The amended bank line of credit required a personal guarantee and cash collateral limited to $100,000, which was provided by Reich Family Limited Partnership. On April 25, 2013, we re-paid $100,735, which represented the principal and interest that was due under the amended bank line of credit. On May 1, 2013, the amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled, and the cash collateral was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013, 2012, and 2011, we paid $735, $7,366, and $5,650, respectively, of interest expense, which are included in interest expense on the accompanying consolidated financial statements.
	Issuance of Promissory Notes
	In January and February 2012, we issued 6% promissory notes in the aggregate principal amount of $900,000, due March 1, 2012. As discussed below in Issuance and Settlement of February 2012 Notes, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory notes.
	Issuance and Settlement of February 2012 Notes
	On February 24, 2012, we issued promissory notes, the February 2012 Notes, to an individual and an entity, or the Parties, both of which are stockholders of our company, in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of 9,000,000 shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received an aggregate of $1,000,000 of new funding from the Parties upon issuance of the February 2012 Notes and related warrants and surrender by the Parties of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the aggregate accrued interest of $15,124 (collectively known as the “Prior Notes”). Under the February 2012 Notes, we borrowed an additional $3,000,000 from the Parties during March, April, and May 2012.
	We granted 5,685,300 warrants in consideration of the modification of the Prior Notes and 3,314,700 warrants with the February Funding. We determined that the resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, Modifications and Extinguishments. As such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued in consideration of the modification were expensed (see Warrant Activity During 2012 in NOTE 10 for more details). The fair value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,383 and recognized a loss on extinguishment of debt of $10,307,864, which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair value as of the date of the modification on the accompanying consolidated financial statements.
	On June 19, 2012, we settled an aggregate amount of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase 8,145,486 shares of our Common Stock. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the June 2012 Notes (see NOTE 10 for more details).
	Issuance and Payment of June 2012 Notes
	On June 19, 2012, we issued secured promissory notes, or the June 2012 Notes, to the Parties in the principal amounts of $2,347,128 and $2,344,719, respectively, pursuant to the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively, which sums included principal and accrued interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding from the Parties, or the June Funding. The principal amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June 2012 Notes, we entered into a Security Agreement and pledged all of our assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares of our Common Stock in connection with the June Funding. On March 21, 2013, we repaid $4,882,019, including accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013 on the June 2012 Notes. On April 25, 2013, the balance of accrued interest was paid in full.
	Issuance and Payment of Additional Notes in 2012
	In August and September 2012, we issued 6% promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were paid in full in October 2012.
	In September 2012, we issued a 6% promissory note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.
	Conversion of July 2011 Secured Notes
	In July 2011, VitaMed issued two senior secured promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon the merger and bore interest at the rate of 6% per annum, were due on the one year anniversary thereof, and were convertible into shares of our Common Stock at our option. We were permitted to satisfy the obligation underlying the Secured Notes by delivering such number of shares of our Common Stock calculated by dividing the then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the “Share Price” meant the lower of the most recent price at which we offered and sold shares of our Common Stock (not including any shares of our Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement to convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of $1,054,647 into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial conversion feature of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial statements. For the years ended December 31, 2012 and 2011, we recorded an aggregate of $33,204 and $21,453, respectively, as interest expense on the accompanying consolidated financial statements.
	Issuance of VitaMed Promissory Notes
	In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, we granted warrants to purchase an aggregate of 613,718 shares of our Common Stock. The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon the closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the VitaMed Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Notes in the aggregate of $300,000 were extended. In October 2011, one of the VitaMed Notes for $50,000 was paid in full, and, by mutual agreement, certain of the VitaMed Notes in the aggregate amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held by an unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr. Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate amount of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes in full, including $5,341 in accrued interest.
	In September and October 2011, VitaMed issued convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible Notes bore interest at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt Conversion Agreements with the holders of VitaMed Convertible Notes, pursuant to which we converted the principal and accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common Stock on the date of conversion.
	In December 2011, we issued 4% promissory notes to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr. Finizio in full, including $888 in accrued interest. Mr. Milligan’s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan’s promissory note in full, including $1,519 in accrued interest.
	For the years ended December 31, 2012 and 2011, we recorded an aggregate of $6,344 and $2,390, respectively, as interest expense on the accompanying consolidated financial statements.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 10 – STOCKHOLDERS’ EQUITY
	Preferred Stock
	At December 31, 2013, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were outstanding.
	Common Stock
	At December 31, 2013, we had 250,000,000 shares of Common Stock authorized for issuance, of which 144,976,757 shares of our Common Stock were issued and outstanding.
	Issuances During 2013
	Pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission, or the SEC, on March 14, 2013, we entered into an underwriting agreement with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share, and the Jefferies Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement at a price of $1.58 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our Common Stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.
	On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated, as the representative of the underwriters named therein, or the Stifel Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.
	During 2013 certain individuals exercised their right to purchase shares of our Common Stock. Options to purchase an aggregate of 75,423 shares of our Common Stock were exercised for approximately $31,000. These shares of our Common Stock were issued in part in reliance upon an exemption from the registration provisions of the Securities Act of 1933, or the Act, provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.
	Issuances During 2012
	During 2012, certain individuals exercised their right to purchase shares of our Common Stock. These shares were issued in reliance upon an exemption from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.
		·	Options to purchase an aggregate of 1,691,393 shares of our Common Stock were exercised for $191,000.
		·	Using the cashless exercise feature, options to purchase an aggregate of 240,395 shares of our Common Stock were exercised.
	During June 2012, we settled $3,102,000 in principal and accrued interest of the February 2012 Notes in exchange for the Parties’ exercise of a portion of the related warrants for an aggregate of 8,145,486 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. During June 2012, we and the Parties also agreed to convert a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012, totaling $1,054,647, into 2,775,415 shares of our Common Stock at $0.38 per share. The shares were issued in reliance upon an exemption from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.
	In September 2012, we entered into a Securities Purchase Agreement with multiple investors, relating to the issuance and sale of our Common Stock in a private placement. The private placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of our Common Stock at $2.15 per share, for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies served as our exclusive placement agent. Jefferies’ compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses of the investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. The shares were issued in reliance upon the exemptions from registration under the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. The shares were issued directly by us and did not involve a public offering. The investors were “accredited investors” as that term is defined in Rule 501 of Regulation D and acquired our Common Stock for investment only and not with a present view toward, or for resale in connection with, the public sale or distribution thereof. Pursuant to the terms of the Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares, which we filed on November 27, 2012.
	Issuances During 2011
	In December 2011, a former director of VitaMed, exercised options to purchase 92,057 shares of our Common Stock for an aggregate exercise price of $17,250.
	In October and November 2011, we converted principal and accrued interest in the aggregate of $849,137 into shares of our Common Stock totaling 20,266,822 and 1,415,136, respectively (as more fully described in NOTE 9).
	On October 5, 2011, we entered into a Stock Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company, or Pernix. Pursuant to the terms of the Stock Purchase Agreement, Pernix agreed to purchase 2,631,579 shares of our Common Stock at a purchase price of $0.38 per share for a total purchase price of $1,000,000. Pernix is a related party. For further details, see NOTE 12
	On October 3, 2011, we effected a reverse split of our 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1- for -100, resulting in 165,856 shares issued and outstanding thereafter.
	Warrants
	As of December 31, 2013, we had warrants outstanding to purchase an aggregate of 14,293,499 shares of our Common Stock with a weighted-average contractual remaining life of 3.9 years, and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.79 per share.
	The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.
	Warrant Activity During 2013
	In January 2013, we granted warrants to purchase 1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE 9). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the issuance using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. At December 31, 2013, $260,022 was reported as deferred financing costs included in other current assets in the accompanying consolidated balance sheet and is being amortized over the life of the Plato Note. As of December 31, 2013, $1,451,934 was recorded as financing costs on the accompanying consolidated financial statements.
	In May 2013, we entered into a consulting agreement with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug Products. These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:
		1	283,333 shares were earned on May 11, 2013 upon successful filing of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment of vulvar and vaginal atrophy; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation in the accompanying consolidated financial statements;
		2	283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. At December 31, 2013 we had $154,068 recorded as prepaid expense-short term and $308,128 recorded as prepaid expense-long term in the accompanying consolidated financial statements. During the year ended December 31, 2013, we recorded $77,034 as non-cash compensation in the accompanying consolidated financial statements; and
		3	283,334 shares will vest upon the receipt by us of any final FDA approval of a Drug Product that SCI helped us design. It is anticipated that this event will not occur before December 2015.
	Warrant Activity During 2012
	In February 2012, we issued an aggregate of 5,685,300 Warrants in connection with the modification of certain existing promissory notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection with the issuance of the February 2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants have a fair value of $10,505,247, and the February 2012 Warrants have a fair value of $6,124,873. Fair value was determined on the date of the issuance using a term of five years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment of debt in the accompanying consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining unamortized debt discount.
	In March 2012, we issued an aggregate of 31,000 Warrants to five unaffiliated individuals for services rendered. These Warrants were valued on the date of the issuance using a term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; we recorded $29,736 as consulting expense in the accompanying consolidated financial statements.
	In May 2012, we issued an aggregate of 1,300,000 Warrants to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The Warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2013, we had $360,528 reported as prepaid expense-short term and $593,127 recorded as prepaid expense-long term. During the year ended December 31, 2013 and the year ended December 31, 2012, we recorded $360,528 and $218,045, respectively as non-cash compensation in the accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product. Based on the review, we have determined that the process will take approximately five years. As a result, we are amortizing the $1,532,228 over five years.
	In June 2012, we granted aggregate of 7,000,000 Warrants in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 9). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share. The fair value of the June 2012 Warrants of $9,424,982 was determined on the date of the issuance using a term of five years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the issuance. Of the $1,649,890, $547,210 was amortized to interest expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, we amortized the remaining unamortized debt discount of $1,102,680 to interest expense.
	In June 2012, we issued an aggregate of 1,500 Warrants to three unaffiliated individuals for services rendered. The Warrants were valued on the date of the issuance using a term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of 0%. A total of $1,656 was recorded as consulting expense in the accompanying consolidated financial statements.
	Warrant Activity During 2011
	In December 2011, we issued 500 Warrants with a fair value of $338 to an unrelated individual for consulting services covered under a three-month agreement. The Warrants were valued on the date of the issuance using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield of 0%. The Warrants vested immediately. As of December 31, 2011, of the $338 fair value, $15 was recorded as non-cash compensation and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.
	In October 2011, we issued 600,000 Warrants with a fair value of $133,045 to an officer of our company for services performed. The Warrants were valued on the date of the issuance using an exercise price of $0.38; a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%. The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44). For the years ended December 31, 2013, 2012 and 2011, we recognized $36,284, $36,284 and $7,158, as non-cash compensation in the accompanying consolidated financial statements.
	In December 2011, we issued 184,211 Warrants with a fair value of $25,980 to an unrelated entity for consulting services covered under a two month agreement. The Warrants were valued on the date of the issuance using an exercise price of $0.38; a term of five years; volatility of 41.04%; risk free rate of 1.08%; and a dividend yield of 0%. For the year ended December 31, 2011, the $25,980 fair value was recorded as financing expense.
	In December 2011, VitaMed entered into a two-year consulting agreement with an entity providing help to evaluate improvements to existing products and new products as well as services, including research, design, compliance, scientific and regulatory affairs, and commercialization of products. As compensation, the consultant received 800,000 fully vested and non forfeitableWarrants. The Warrants were valued on the date of the issuance using an exercise price of $0.38; a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $177,394 at the date of grant and was amortized to research and development expense over the life of the agreement which is when the research and development activities were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $71,688, $95,582 and $10,124, respectively, in research and development expenses related to this agreement.
	In July 2011, VitaMed also entered into a one-year consulting agreement with the same consultant, whereby Consultant would assist in the design, development, and distribution efforts of VitaMed’s initial product offering. As compensation, the Consultant received 200,000 fully vested non forfeitable VitaMed Warrants (or a Warrant for 245,485 shares pursuant to the Conversion Ratio). The VitaMed Warrant was valued on the date of the grant at $12,548 using an exercise price of $0.41; a term of five years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $12,548 at the date of grant and was amortized to research and development expense over the life of the agreement which is when the research and development activities were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $0, $6,936 and $5,612 respectively, in research and development expenses related to this agreement. In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate of $500,000 with 500,000 accompanying VitaMed Warrants (or Warrants for an aggregate of 613,718 shares of our Common Stock taking into account the merger). The VitaMed Warrants were valued on the date of the issuance using an exercise price of $0.41; a term of five years; a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%. The Warrants vested immediately. Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial statements.
	In March 2011, VitaMed entered into a business loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required. Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited LP (See NOTE 9 for more details). In consideration for the personal guarantees and cash collateral, VitaMed issued an aggregate of 499,998 VitaMed Warrants (or Warrants for an aggregate of 613,713 shares of our Common Stock taking into account the merger). The ten-year Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.24 per share. On November 13, 2012, the outstanding balance was repaid in full and business loan agreement was amended to reflect a $100,000 bank line of credit. As part of the amended line of credit, the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Warrants, Warrants previously issued to Mr. Finizio and Mr. Milligan were amended to reflect the amount vested prior to the date of the amended line of credit (179,000 each). At December 31, 2013, an aggregate of 562,571 Warrants were vested. The Warrants, with a fair value of $93,969 ($86,139 after adjusting for the effect of the amended line of credit ), were valued on the date of the issuance using a term of 10 years; a volatility of 47.89%; risk free rate of 3.48%; and a dividend yield of 0%. For the years ended December 31, 2013, 2012 and 2011, $2,944, $45,036 and $38,159, respectively was recorded as loan guaranty costs in other income and expense on the accompanying consolidated financial statements.
	Summary of our Warrant activity and related information for 2011-2013
			Number of Shares Under Warrants			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years			Aggregate Intrinsic Value
	Balance at December 31, 2010			─
	Issued			3,057,627		$	0.36			7.9		$	3,483,691
	Exercised			─
	Expired			─
	Cancelled			─
	Balance at December 31, 2011			3,057,627		$	0.36			7.9		$	3,483,691
	Issued			17,332,500		$	1.26			4.3		$	31,891,150
	Exercised			(8,145,486	)	$	0.38
	Expired			─
	Cancelled			(51,142	)	$	0.24
	Balance at December 31, 2012			12,193,499		$	1.63					$	17,971,994
	Issued			2,100,000		$	2.72			4.8		$	5,232,500
	Exercised			─
	Expired			─
	Cancelled			─
	Balance at December 31, 2013			14,293,499		$	1.79			3.9		$	48,932,777
	Vested and Exercisable at December 31, 2013			13,764,710		$	1.81			3.9		$	46,840,559
	As of December 31, 2013, we had warrants outstanding with exercise prices ranging from $0.24 to $3.20 per share. As of December 31, 2013, unamortized costs associated with warrants totaled approximately $1,599,000.
	The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are set forth in the table below.
		2013			2012			2011
Weighted average fair value		$	2.83		$	2.05		$	0.16
Risk-free interest rate			0.88-1.12	%		0.72-1.04	%		0.91-3.48	%
Volatility			44.29-45.89	%		44.64-44.81	%		39.13-51.83	%
Term (in years)			6-May			5			10-May
Dividend yield			0	%		0	%		0	%
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.
Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2013.
Options to Purchase Common Stock of the Company
In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger, no awards had been issued under the 2009 Plan. As of December 31, 2013 there were 13,632,742 shares of our Common Stock issued under the 2009 Plan.
On February 23, 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2013, there were 2,650,000 shares issued under the 2012 Plan.
The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.
		2013			2012			2011
Risk-free interest rate			0.65-1.71	%		0.61-2.23	%		0.91-2.54	%
Volatility			33.35-45.76	%		40.77-46.01	%		37.92-40.48	%
Term (in years)			5-6.25			5-6.25			5.5-6.25
Dividend yield			0	%		0	%		0	%
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual term of the option using the simplified method.
A summary of activity under the 2009 and 2012 Plans and related information for 2011-2013 follows:
		Number of Shares Under Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years			Aggregate Intrinsic Value
Balance at December 31, 2010			─
Granted(1)			10,682,218		$	0.16			7.6		$	14,188,484
Exercised			(92,057	)	$	0.19
Expired			─
Cancelled			─
Balance at December 31, 2011			10,590,161		$	0.16			7.6		$	14,067,649
Granted			5,121,250		$	2.8			9.7		$	1,737,530
Exercised			(1,931,788	)	$	0.13
Expired			─
Cancelled			(46,135	)
Balance at December 31, 2012			13,733,488		$	1.16			7.7		$	26,804,117
Granted			2,583,677		$	3.31			9.8		$	4,920,981
Exercised			(75,423	)
Expired			(250	)
Cancelled			(608,750	)
Balance at December 31, 2013			15,632,742		$	1.44			7.2		$	58,878,132
Vested and Exercisable at December 31, 2013			11,282,627		$	0.8			6.5		$	48,321,930
(1)This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.
At December 31, 2013, our outstanding options had exercise prices ranging from $0.10 to $4.67 per share.
Share-based compensation expense for options recognized in our results for the years ended December 31, 2013, 2012, and 2011 ($3,200,655, $1,832,061, and $183,355, respectively) is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.
At December 31, 2013, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $3,921,000, which is expected to be recognized over a weighted-average period of 1.3 years. No tax benefit was realized due to a continued pattern of operating losses. At December 31, 2012 and 2011, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $4,391,000 and $244,000, respectively.
In December 2013, we issued a restricted stock unit, or the RSU, under our 2012 Plan to an officer for the purchase of 50,000 shares of our Common Stock. The RSU will vest on April 1, 2014 and has a fair value of $233,500. As of December 31, 2013, we recorded $53,428 of non-cash compensation.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 11 – INCOME TAXES
	For the years ended December 31, 2013, 2012 and 2011, there was no provision for income taxes, current or deferred.
	At December 31, 2013, we have a federal net operating loss carry forward of approximately $37,000,000 available to offset future taxable income through 2033.
	At December 31, 2013, 2012, and 2011, we have state net operating loss carryforwards of approximately $35,000,000 available to offset future losses through 2033. We established valuation allowances equal to the full amount of the deferred tax assets because of the uncertainty of the utilization of the operating losses in future periods. We periodically assess the likelihood that we will be able to recover the deferred tax assets. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income.
	Our deferred tax asset and liability as presented in the accompanying consolidated financial statements consist of the following:
		2013			2012			2011
	Deferred Income Tax Assets:
	Net operating losses	$	14,773,537		$	5,920,861		$	748,404
	R&D Credit		547,511			186,346
	Total deferred income tax asset		15,321,048			6,107,207			748,404
	Valuation allowance		(15,321,048	)		(6,107,207	)		(748,404	)
	Deferred Income Tax Assets, net	$	-0-		$	-0-		$	-0-
	Our provision for income taxes differs from applying the statutory U.S. federal income tax rate to the income before income taxes. The primary differences result from deducting certain expenses for financial statement purposes but not for federal income tax purposes.
	A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:
		2013			2012			2011
	Federal statutory tax rate		35	%		35	%		35	%
	State tax rate, net of federal tax benefit		5.8	%		5.5	%		-0-	%
	Adjustment in valuation allowances		(32.4	)%		(18.2	)%		(5.8	)%
	Permanent and other differences		(8.4	)%		(22.3	)%		(29.2	)%
	Provision (Benefit) for Income Taxes		-0-	%		-0-	%		-0-	%

RELATED_PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
	NOTE 12 – RELATED PARTIES
	Loan Guaranty
	In March 2011, VitaMed entered into a business loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required. Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited Limited Partnership. See NOTES 9 and 10 for more details.
	Loans from Affiliates
	In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the affiliate notes were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC, which is owned by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Promissory Notes were paid in full including $5,341 in accrued interest.
	In December 2011, we issued 4% promissory notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio was paid in full, including $888 in accrued interest. Mr. Milligan’s VitaMed Promissory Note was extended to October 15, 2012. On October 4, 2012 this VitaMed Notes was paid in full including $1,519 in accrued interest.
	Lock Up Agreements
	As required by the terms of the merger agreement with VitaMed dated July 18, 2011, we entered into Lock-Up Agreements with stockholders covering the aggregate of 70,000,000 shares of our Common Stock issued pursuant to the merger or reserved for issuance pursuant to stock options and warrants. Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder’s aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.
	Purchases by Related Parties
	During 2013, 2012, and 2011, we sold our products to Dr. Brian Bernick, a director of our company, in the amounts of $0, $2,632 and $20,669, respectively, while $0, $1,272 and $0 of receivables related thereto remained outstanding at December 31, 2013, 2012 and 2011, respectively.
	Agreements with Pernix Therapeutics, LLC
	On February 29, 2012, Cooper C. Collins, President and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. We closed a stock purchase agreement with Pernix on October 5, 2011. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors. During the years ended December 31, 2013, 2012, and 2011, we made purchases of approximately $0, $404,000 and $19,000, respectively, from Pernix. At December 31, 2013, 2012, and 2011, there were amounts due Pernix of approximately $46,000, $308,000 and 19,000 outstanding, respectively.
	Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement, in the amounts of $249,981 and $0 for the periods ending December 31, 2013 and December 31, 2012, respectively.
	Warrants assigned to Related Party
	In June 2012, a warrant to purchase 100,000 shares of our Common Stock was assigned to the son of the Chairman of our board of directors by a non-affiliated third party.

BUSINESS_CONCENTRATIONS

BUSINESS CONCENTRATIONS	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
BUSINESS CONCENTRATIONS	'
	NOTE 13 - BUSINESS CONCENTRATIONS
	We purchase our products from several suppliers with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and 2011, respectively.
	We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health, Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December 31, 2013, 2012, and 2011, respectively.
	For the years ended December 31, 2013 and 2012, 64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers in prior years.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 14 – COMMITMENTS AND CONTINGENCIES
	Operating Lease
	We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.
	The straight line rental expense related to our current lease totaled $180,894 for the six months ended December 31, 2013 offset by rent income of $32,963. The rental expense related to our prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 and $122,752 for the years ended December 31, 2012 and 2011, respectively.
	As of December 31, 2013, future minimum rental payments are as follows:
	Years Ending December 31,
	2014	$	316,039
	2015		371,240
	2016		382,377
	2017		393,848
	2018		302,748
	Total minimum lease payments		1,766,252
	Noncancelable sub-lease income		(38,956	)
	Net minimum lease payments	$	1,727,296

SELECTED_QUARTERLY_FINANCIAL_D

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	'
	NOTE 15 – SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	Summarized quarterly financial data for fiscal years 2013 and 2012 is as follows:
		2013 Quarters
	(In thousands, except per share)		1st			2nd			3rd			4th
	Revenues	$	1,537		$	2,081		$	2,295		$	2,863
	Gross profit	$	1,157		$	1,617		$	1,646		$	2,396
	Net loss	$	(6,376	)	$	(6,009	)	$	(7,673	)	$	(8,361	)
	Loss per common share, basic and diluted	$	(0.06	)	$	(0.05	)	$	(0.06	)	$	(0.06	)
		2012 Quarters
	(In thousands, except per share)		1st			2nd			3rd			4th
	Revenues	$	722		$	819		$	1,036		$	1,241
	Gross profit	$	386		$	447		$	729		$	908
	Net loss	$	(13,290	)	$	(11,850	)	$	(4,253	)	$	(5,727	)
	Loss per common share, basic and diluted	$	(0.16	)	$	(0.14	)	$	(0.04	)	$	(0.06	)

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 16_ – SUBSEQUENT EVENTS
	On January 6, 2014, options for 390,000 shares of stock were granted to certain members of our Board of Directors under the 2012 Plan for their services to be rendered in 2014. The options were granted for a period of 10 years at an exercise price equal to the closing price at the date of grant, and vest on December 31, 2014.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances and transactions have been eliminated in consolidation.
Cash	'
	Cash
	We maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured limits.
Trade Accounts Receivable and Allowance for Doubtful Accounts	'
	Trade Accounts Receivable and Allowance for Doubtful Accounts
	Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance for doubtful accounts when received. To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required.
Inventories	'
	Inventories
	Inventories represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time as the related deferred revenue is recognized.
Fixed Assets	'
	Fixed Assets
	Equipment
	We state equipment at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expense as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years.
	Leasehold Improvements
	We state improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining term of the lease.
Intangible Assets	'
	Intangible Assets
	Patent and Trademarks
	We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, Intangible-Goodwill and Other, or ASC 350. Capitalized patent costs, net of accumulated amortization, include legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted in the year ended December 31, 2013.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:
		·	significant declines in an asset’s market price;
		·	significant deterioration in an asset’s physical condition;
		·	significant changes in the nature or extent of an asset’s use or operation;
		·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying value. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Our financial instruments consist primarily of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which would be considered Level 3 inputs under the fair value hierarchy.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, Fair Value Measurements and Disclosures. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).
	Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At December 31, 2013, 2012, and 2011, we had no assets or liabilities that were valued at fair value on a recurring basis.
Income Taxes	'
	Income Taxes
	With the advent of the Merger, we determined that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.
	We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.
	In accordance with ASC 740, Income Taxes, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.
	We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating to open tax returns that were considered to be uncertain.
	Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.
Share-Based Compensation	'
	Share-Based Compensation
	In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of the award.
	Equity instruments (“instruments”) issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC 505, Equity Based Payments to Non-Employees, or ASC 505, defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.
	We recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period.
Debt Discounts	'
	Debt Discounts
	Costs incurred from parties that are providing long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the related debt using the effective interest rate method.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.
	Over-the-Counter Products
	We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.
	Prescription Products
	We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and rebates.
	We accept returns of unsalable product from customers within a return period of six months prior to and following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return.
	We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	We expense all shipping and handling costs as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.
Advertising Costs	'
	Advertising Costs
	We expense advertising costs when incurred. Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31, 2012, respectively.
Research and Development	'
	Research and Development Expenses
	Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future R&D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.
Earnings Per Share	'
	Earnings Per Share
	We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these periods because their effect would have been anti-dilutive due to the net loss reported by us.
Use of Estimates	'
	Use of Estimates
	Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.
Recently Issued and Newly Adopted Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In July, 2013, the FASB issued Accounting Standards Update, or ASU, No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial statements.
	In July 2012, the FASB issued ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 gives entities an option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.
	In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our financial position or results of operations.
	We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.
Reclassifications	'
	Reclassifications
	Certain 2012 amounts have been reclassified to conform to current year presentation.

INVENTORY_Tables

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consists of the following:
		December 31,
		2013		2012
	Finished product	$	621,679	$	1,124,739
	Raw material		250,943		380,000
	Deferred costs		170,996		110,471
	TOTAL INVENTORY	$	1,043,618	$	1,615,210

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Other Assets:	'
Schedule of other current assets	'
	Other current assets consist of the following:
		December 31,
		2013		2012
	Prepaid R&D costs	$	1,267,588	$	189,375
	Prepaid consulting		530,596		432,216
	Deferred financing costs		260,022		─
	Other receivable – related party		249,981		─
	Prepaid other		169,528		127,403
	Prepaid guaranty costs		─		2,944
	TOTAL OTHER CURRENT ASSETS	$	2,477,715	$	751,938

FIXED_ASSETS_Tables

FIXED ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of fixed assets	'
	Fixed assets consist of the following:
		December 31,
		2013			2012
	Equipment	$	108,458		$	67,668
	Furniture and fixtures		46,625			46,625
	Leasehold improvements		─			11,980
			155,083			126,273
	Accumulated depreciation		(93,765	)		(60,600	)
	TOTAL FIXED ASSETS	$	61,318		$	65,673

PREPAID_EXPENSE_Tables

PREPAID EXPENSE (Tables)	12 Months Ended
	Dec. 31, 2013
Prepaid Expense, Current [Abstract]	'
Schedule of prepaid expense	'
	Prepaid expense consists of the following:
		December 31,
		2013		2012
	Prepaid R & D costs	$	824,221	$	953,655
	Prepaid manufacturing costs		899,000		─
	Accreted prepaid costs		27,234		─
	TOTAL PREPAID EXPENSE	$	1,750,455	$	953,655

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of intangible assets	'
	The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2013 and December 31, 2012:
		December 31, 2013
		Gross		Accumulated			Net		Weighted-
		Carrying		Amortization			Amount		Average
		Amount							Amortization
									Period (yrs.)
	Amortizing intangible assets:
	OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
	Development costs for corporate website		91,743		(89,661	)		2,082		0.3
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents		572,726		—			572,726		n/a
	Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
	Total	$	755,748	$	(90,160	)	$	665,588
		December 31, 2012
		Gross		Accumulated			Net		Weighted-
		Carrying		Amortization			Amount		Average
		Amount							Amortization
									Period (yrs.)
	Amortizing intangible assets:
	OPERA ® software patent	$	23,722	$	0		$	23,722		0
	Development costs for corporate website		91,743		(77,159	)		14,584		1.3
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents		180,194		—			180,194		n/a
	Multiple trademarks for vitamins/supplements		21,055		—			21,055		n/a
	Total	$	316,714	$	(77,159	)	$	239,555
Schedule of estimated amortization expense	'
	Estimated amortization expense for the next five years is as follows:
	Year Ending December 31,	Estimated Amortization
	2014	$	4,080
	2015		1,997
	2016		1,997
	2017		1,997
	2018		1,997

OTHER_CURRENT_LIABILITIES_Tabl

OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Noncontrolling Interest [Abstract]	'
Schedule of other current liabilities	'
	Other current liabilities consist of the following:
		December 31,
		2013		2012
	Accrued payroll and commission costs	$	941,313	$	397,210
	Accrued financing costs		850,000		─
	Accrued vacation		256,920		114,899
	Allowance for wholesale distributor fees		306,303		107,784
	Accrued legal and accounting expense		224,550		90,000
	Accrued lab research		536,574		─
	Accrued clinical trial costs		129,208		─
	Allowance for coupons and returns		126,233		53,002
	Other accrued expenses(1)		230,088		70,759
	TOTAL OTHER CURRENT LIABILITIES	$	3,601,189	$	833,654
	(1) In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of warrant activity	'
	Summary of our Warrant activity and related information for 2011-2013
		Number of Shares Under Warrants			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years			Aggregate Intrinsic Value
	Balance at December 31, 2010		─
	Issued		3,057,627		$	0.36			7.9		$	3,483,691
	Exercised		─
	Expired		─
	Cancelled		─
	Balance at December 31, 2011		3,057,627		$	0.36			7.9		$	3,483,691
	Issued		17,332,500		$	1.26			4.3		$	31,891,150
	Exercised		(8,145,486	)	$	0.38
	Expired		─
	Cancelled		(51,142	)	$	0.24
	Balance at December 31, 2012		12,193,499		$	1.63					$	17,971,994
	Issued		2,100,000		$	2.72			4.8		$	5,232,500
	Exercised		─
	Expired		─
	Cancelled		─
	Balance at December 31, 2013		14,293,499		$	1.79			3.9		$	48,932,777
	Vested and Exercisable at December 31, 2013		13,764,710		$	1.81			3.9		$	46,840,559
Schedule of weighted average fair value per share and assumptions used in the Black-Scholes Model of warants	'
	The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are set forth in the table below.
		2013			2012			2011
	Weighted average fair value	$	2.83		$	2.05		$	0.16
	Risk-free interest rate		0.88-1.12	%		0.72-1.04	%		0.91-3.48	%
	Volatility		44.29-45.89	%		44.64-44.81	%		39.13-51.83	%
	Term (in years)		6-May			5			10-May
	Dividend yield		0	%		0	%		0	%
Schedule of assumptions used in the Black-Scholes Model of stock options	'
	The assumptions used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.
		2013			2012			2011
	Risk-free interest rate		0.65-1.71	%		0.61-2.23	%		0.91-2.54	%
	Volatility		33.35-45.76	%		40.77-46.01	%		37.92-40.48	%
	Term (in years)		5-6.25			5-6.25			5.5-6.25
	Dividend yield		0	%		0	%		0	%
Schedule of Option activity	'
	A summary of activity under the 2009 and 2012 Plans and related information for 2011-2013 follows:
		Number of Shares Under Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years			Aggregate Intrinsic Value
	Balance at December 31, 2010		─
	Granted(1)		10,682,218		$	0.16			7.6		$	14,188,484
	Exercised		(92,057	)	$	0.19
	Expired		─
	Cancelled		─
	Balance at December 31, 2011		10,590,161		$	0.16			7.6		$	14,067,649
	Granted		5,121,250		$	2.8			9.7		$	1,737,530
	Exercised		(1,931,788	)	$	0.13
	Expired		─
	Cancelled		(46,135	)
	Balance at December 31, 2012		13,733,488		$	1.16			7.7		$	26,804,117
	Granted		2,583,677		$	3.31			9.8		$	4,920,981
	Exercised		(75,423	)
	Expired		(250	)
	Cancelled		(608,750	)
	Balance at December 31, 2013		15,632,742		$	1.44			7.2		$	58,878,132
	Vested and Exercisable at December 31, 2013		11,282,627		$	0.8			6.5		$	48,321,930
	(1)This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of deferred tax assets and liabilities	'
	Our deferred tax asset and liability as presented in the accompanying consolidated financial statements consist of the following:
		2013			2012			2011
	Deferred Income Tax Assets:
	Net operating losses	$	14,773,537		$	5,920,861		$	748,404
	R&D Credit		547,511			186,346
	Total deferred income tax asset		15,321,048			6,107,207			748,404
	Valuation allowance		(15,321,048	)		(6,107,207	)		(748,404	)
	Deferred Income Tax Assets, net	$	-0-		$	-0-		$	-0-
Schedule of tax rate reconciliation	'
	A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:
		2013			2012			2011
	Federal statutory tax rate		35	%		35	%		35	%
	State tax rate, net of federal tax benefit		5.8	%		5.5	%		-0-	%
	Adjustment in valuation allowances		(32.4	)%		(18.2	)%		(5.8	)%
	Permanent and other differences		(8.4	)%		(22.3	)%		(29.2	)%
	Provision (Benefit) for Income Taxes		-0-	%		-0-	%		-0-	%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Tables	'
Schedule of future minimum rental payments	'
	As of December 31, 2013, future minimum rental payments are as follows:
	Years Ending December 31,
	2014	$	316,039
	2015		371,240
	2016		382,377
	2017		393,848
	2018		302,748
	Total minimum lease payments		1,766,252
	Noncancelable sub-lease income		(38,956	)
	Net minimum lease payments	$	1,727,296

SELECTED_QUARTERLY_FINANCIAL_D1

SELECTED QUARTERLY FINANCIAL DATA (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of quarterly unaudited summary information	'
	Summarized quarterly financial data for fiscal years 2013 and 2012 is as follows:
		2013 Quarters
	(In thousands, except per share)		1st			2nd			3rd			4th
	Revenues	$	1,537		$	2,081		$	2,295		$	2,863
	Gross profit	$	1,157		$	1,617		$	1,646		$	2,396
	Net loss	$	(6,376	)	$	(6,009	)	$	(7,673	)	$	(8,361	)
	Loss per common share, basic and diluted	$	(0.06	)	$	(0.05	)	$	(0.06	)	$	(0.06	)
		2012 Quarters
	(In thousands, except per share)		1st			2nd			3rd			4th
	Revenues	$	722		$	819		$	1,036		$	1,241
	Gross profit	$	386		$	447		$	729		$	908
	Net loss	$	(13,290	)	$	(11,850	)	$	(4,253	)	$	(5,727	)
	Loss per common share, basic and diluted	$	(0.16	)	$	(0.14	)	$	(0.04	)	$	(0.06	)

THE_COMPANY_Details_Narrative

THE COMPANY (Details Narrative)	0 Months Ended				0 Months Ended
	Jul. 28, 2011	Dec. 31, 2013	Dec. 31, 2012	Jul. 29, 2011	Oct. 04, 2011	Jul. 29, 2011	Jul. 28, 2011	Oct. 04, 2011	Oct. 04, 2011
					Agreement and Plan of Merger with VitaMed	Agreement and Plan of Merger with VitaMed	Agreement and Plan of Merger with VitaMed	Agreement and Plan of Merger with VitaMed	Agreement and Plan of Merger with VitaMed
								Options	Warrants
Common stock, shares issued	16,575,209	144,976,757	99,784,982	165,856	'	165,856	16,575,209	'	'
Common stock, shares outstanding	16,575,209	144,976,757	99,784,982	165,856	'	165,856	16,575,209	'	'
Reverse stock split ratio	'1 for 100	'	'	'	'	'1 for 100	'	'	'
Percentage decrease in holding due to merger	'	'	'	'	'	99.00%	'	'	'
Common stock, shares authorized	'	250,000,000	250,000,000	'	250,000,000	'	'	'	'
Percentage of holding acquired	'	'	'	'	100.00%	'	'	'	'
Shares issued in exchange for outstanding membership units	'	'	'	'	58,407,331	'	'	'	'
Shares reserved for future isssuance	'	'	'	'	70,000,000	'	'	10,119,796	1,472,916
Description of lock in period	'	'	'	'	'Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Advertising Costs	$11,739	$19,480	$65,944
Advance payments for future research and development activities	$2,091,809	$189,375	'
Anti-dilutive shares excluded from earnings per share calculation	29,926,241	25,926,987	13,647,788
Equipment | Maximum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives	'7 years	'	'
Equipment | Minimum	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Estimated useful lives	'3 years	'	'

INVENTORY_Details

INVENTORY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory	'	'
Finished Product	$621,679	$1,124,739
Raw Material	250,943	380,000
Deferred Costs	170,996	110,471
Inventory	$1,043,618	$1,615,210

OTHER_CURRENT_ASSETS_Details

OTHER CURRENT ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Current Assets	'	'
Prepaid R&D costs	$1,267,588	$189,375
Prepaid consulting	530,596	432,216
Deferred financing costs	260,022	'
Other receivables-related party	249,981	'
Prepaid other	169,528	127,403
Prepaid guaranty costs	'	2,944
TOTAL OTHER CURRENT ASSETS	$2,477,715	$751,938

FIXED_ASSETS_Details_Narrative

FIXED ASSETS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Depreciation Expense	$47,883	$27,484	$25,686
Leasehold Improvements	'	'	'
Decrease accumulated depreciation	$11,980	'	'

FIXED_ASSETS_Details

FIXED ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fixed assets, gross	$155,083	$126,273
Accumulated depreciation	-93,765	-60,600
Fixed Assets, net	61,318	65,673
Equipment	'	'
Fixed assets, gross	108,458	67,668
Furniture and Fixtures	'	'
Fixed assets, gross	46,625	46,625
Leasehold Improvements	'	'
Fixed assets, gross	'	$11,980

PREPAID_EXPENSE_Details

PREPAID EXPENSE (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Assets	'	'
Prepaid R&D costs	$824,221	$953,655
Prepaid manufacturing costs	899,000	'
Accreted prepaid costs	27,234	'
TOTAL PREPAID EXPENSE	$1,750,455	$953,655

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'
Amortization expense	$10,262	$28,776	$29,159

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details ) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets	'	'
Accumulated Amortization	($90,160)	($77,159)
Indefinite-Lived Intangible Assets	'	'
Gross Carrying Amount	755,748	316,714
Net Amount	665,588	239,555
Gross Carrying Amount	755,748	316,714
Net Amount	665,588	239,555
Hormone therapy drug candidate patents	'	'
Indefinite-Lived Intangible Assets	'	'
Gross Carrying Amount	572,726	180,194
Net Amount	572,726	180,194
Multiple trademarks for vitamins/supplements	'	'
Indefinite-Lived Intangible Assets	'	'
Gross Carrying Amount	59,328	21,055
Net Amount	59,328	21,055
OPERAB. software patent	'	'
Finite-Lived Intangible Assets	'	'
Gross Carrying Amount	31,951	23,722
Accumulated Amortization	-499	0
Net Amount	31,452	23,722
Weighted Average Amortization Period	'15 years 9 months 18 days	'0 years
Development costs for corporate website	'	'
Finite-Lived Intangible Assets	'	'
Gross Carrying Amount	91,743	91,743
Accumulated Amortization	-89,661	-77,159
Net Amount	$2,082	$14,584
Weighted Average Amortization Period	'0 years 3 months 18 days	'1 year 3 months 18 days

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
2014	$4,080
2015	1,997
2016	1,997
2017	1,997
2018	$1,997

OTHER_CURRENT_LIABILITIES_Deta

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Liabilities, Current [Abstract]	'	'
Dividends Payable, amount per share	$0.40	'
Unclaimed dividends	$41,359	$41,359

OTHER_CURRENT_LIABILITIES_Deta1

OTHER CURRENT LIABILITIES (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Other Liabilities, Current [Abstract]	'		'
Accrued payroll and commission costs	$941,313		$397,210
Accrued financing costs	850,000		'
Accrued vacation	256,920		114,899
Allowance for wholesale distributor fees	306,303		107,784
Accrued legal and accounting expense	224,550		90,000
Accrued lab research	536,574		'
Accrued clinical trial costs	129,208		'
Allowance for coupons and returns	126,233		53,002
Other accrued expenses	230,088	[1]	70,759	[1]
TOTAL OTHER CURRENT LIABILITIES	$3,601,189		$833,654
[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.

NOTES_PAYABLE_Details_Narrativ

NOTES PAYABLE (Details Narrative) (USD $)

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 13, 2012

Nov. 13, 2012

Nov. 13, 2012

Mar. 21, 2013

Mar. 13, 2013

Feb. 25, 2013

Jan. 31, 2013

Dec. 31, 2013

Apr. 25, 2013

Mar. 19, 2012

Feb. 28, 2013

Jun. 30, 2012

Oct. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 13, 2012

Mar. 31, 2011

Mar. 31, 2011

Nov. 13, 2012

Mar. 31, 2011

Feb. 29, 2012

Feb. 24, 2012

31-May-12

Jun. 19, 2012

Jun. 19, 2012

Jun. 30, 2013

Feb. 29, 2012

Feb. 24, 2012

Feb. 24, 2012

Jun. 19, 2012

Jun. 19, 2012

Jun. 19, 2012

Apr. 25, 2013

Mar. 21, 2013

Jun. 19, 2012

Mr. Finizio

Mr. Milligan

Reich Family Limited LP

Multiple Advance Revolving Credit Note (Plato Warrant)

Multiple Advance Revolving Credit Note (Plato Warrant)

Multiple Advance Revolving Credit Note (Plato Warrant)

Multiple Advance Revolving Credit Note (Plato Warrant)

Multiple Advance Revolving Credit Note (Plato Warrant)

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

Issuance of 6% Promissory Notes (January and February 2012)

February 2012 Notes Issued To Individual And Entity

February 2012 Notes Issued To Individual And Entity

February 2012 Notes Issued To Individual And Entity

February 2012 Notes/ Warrants

February 2012 Notes/ Warrants

February 2012 Notes/ Warrants

February 2012 Notes/ Warrants

February 2012 Notes Issued To Parties

February 2012 Notes Issued To Parties

June 2012 Notes Issued To Individual And Entity

June 2012 Notes Issued To Parties

June 2012 Notes (secured promissory notes)

June 2012 Notes (secured promissory notes)

June 2012 Notes (secured promissory notes)

Mr. Finizio

Mr. Milligan

Reich Family Limited LP

Reich Family Limited LP

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum principal amount

'

'

'

'

'

'

'

'

'

$10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stated interest rate

'

'

'

'

'

'

'

'

'

6.00%

'

'

2.35%

'

'

'

'

3.02%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of interest payment

'

'

'

'

'

'

'

'

'

'Interest payments were due and payable on the tenth day following the end of each calendar quarter

'

'

'Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013.

'

'

'

'

'The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from revolving credit note

'

'

'

'

'

'

'

200,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of revolving credit note

'

'

'

'

'

'

401,085

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revolving credit outstanding

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares purchased

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

613,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,685,300

3,314,700

5,685,300

'

'

'

'

'

9,000,000

Exercise price of warrants (in dollars per unit)

'

'

'

'

'

'

'

'

'

3.2

'

'

'

'

'

'

0.41

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.38

'

'

'

'

'

'

'

'

Line of credit

'

'

'

179,000

179,000

179,000

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

299,220

100,000

100,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of lines of credit

500,000

300,000

'

'

'

'

'

'

'

'

'

100,735

'

'

'

'

'

'

'

'

'

'

'

'

299,220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from lines of credit

500,000

'

300,000

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility decrease forgiveness

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

1,165,981

1,905,409

64,380

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

735

7,366

5,650

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

900,000

1,358,014

'

'

'

'

'

'

1,357,110

'

2,347,128

2,344,719

'

'

'

Proceeds from notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

3,000,000

'

'

'

'

'

1,700,000

'

'

2,000,000

'

'

'

Repayments of notes payable

4,691,847

1,850,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

4,882,019

'

Acrued interest

'

150,068

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,124

'

'

'

'

21,595

'

Fair value of notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,517,741

'

'

'

'

'

'

Debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

859,647

'

197,383

'

'

'

'

'

'

Recognized loss on extinguishment of debt

'

-10,307,864

-7,390,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,307,864

'

'

'

'

'

'

Aggregate principal and accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,102,000

'

'

'

'

'

'

'

'

'

'

Amount of shares issued in exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,145,486

8,145,486

'

'

'

'

'

'

'

'

'

Remaining balance of notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,347,128

2,691,847

'

'

'

'

1,344,719

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

Description of interest rate terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014.

Acrued interest paid

$212,853

$17,253

$696

'

'

'

'

'

'

'

'

'

'

'

$2,160

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$21,595

'

'

NOTES_PAYABLE_Details_Narrativ1

NOTES PAYABLE (Details Narrative 1) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2012

Sep. 30, 2012

Oct. 31, 2012

Sep. 30, 2012

Jun. 19, 2012

Dec. 31, 2012

Dec. 31, 2011

Jul. 31, 2011

Jul. 31, 2011

Jul. 31, 2011

Jun. 30, 2012

Nov. 30, 2011

Oct. 30, 2011

Oct. 31, 2011

Jun. 30, 2011

Nov. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 04, 2012

Jun. 30, 2012

Oct. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2012

Oct. 04, 2012

6% Notes issued in August and September 2012

6% Notes issued in August and September 2012

6% Notes issued in September 2012

6% Notes issued in September 2012

VitaMed July 2011 Secured Notes

VitaMed July 2011 Secured Notes

VitaMed July 2011 Secured Notes

VitaMed July 2011 Secured Notes

VitaMed July 2011 First Secured Notes

VitaMed July 2011 Second Secured Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Convertible Notes

Notes Issued to Mr. Finizio And Mr. Milligan

Notes Issued to Mr. Finizio And Mr. Milligan

Notes Issued to Mr. Finizio

Notes Issued to Mr. Milligan

Number

Number

Brian Bernick

Brian Bernick

Number

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

$1,600,000

'

$200,000

'

'

'

'

$500,000

$500,000

'

'

'

'

$500,000

'

'

'

'

'

'

$534,160

'

$100,000

'

'

Repayments of notes payable

4,691,847

1,850,000

200,000

1,600,000

'

200,000

'

'

'

'

'

'

'

'

'

50,000

'

200,000

'

'

'

'

100,000

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

4.00%

'

'

'

'

Aggregate principal and accrued interest

'

'

'

'

'

'

'

1,054,647

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Numbers of shares converted for debt

'

'

'

'

'

'

'

2,775,415

'

'

'

'

'

'

1,415,136

266,822

20,266,822

'

'

'

'

'

'

'

1,415,136

'

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

'

$0.38

'

'

'

'

'

'

'

$0.38

'

'

'

'

'

'

'

'

$0.38

'

'

'

'

Value of debt converted to shares

'

-6,716,504

'

'

'

'

'

6,716,504

'

'

'

'

'

'

'

100,000

'

'

849,137

'

'

'

'

'

'

'

'

'

'

Interest expense

1,165,981

1,905,409

64,380

'

'

'

'

'

33,204

21,453

'

'

'

'

'

'

'

'

'

735

7,366

5,650

'

'

'

6,344

2,390

'

'

Numbers of shares purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

613,718

'

'

'

'

'

'

'

'

'

'

'

Description of interest rate terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding.

'

'

'

'

'

'

'

'

'

'

'

Acrued interest paid

212,853

17,253

696

'

'

'

'

'

'

'

'

'

'

2,160

'

'

'

'

'

'

'

'

5,341

'

'

'

'

888

1,519

Aggregate remaining principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

STOCKHOLDERS_EQUITY_Details_Na

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Jul. 28, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jul. 29, 2011

Oct. 05, 2011

Sep. 30, 2013

Jun. 19, 2012

Jun. 30, 2013

Dec. 31, 2011

Nov. 30, 2011

Oct. 30, 2011

Oct. 31, 2011

Nov. 30, 2011

Apr. 20, 2013

Mar. 20, 2013

Dec. 31, 2013

Sep. 25, 2013

Stock Purchase Agreement With Pernix Therapeutics LLC

Private placement

February 2012 Notes/ Warrants

February 2012 Notes/ Warrants

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

Jefferies LLC (Underwriters)

Jefferies LLC (Underwriters)

Jefferies LLC (Underwriters)

Stifel, Nicolaus & Company (Underwriters)

Number

Preferred stock, shares authorized

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value (in dollars per share)

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares issued

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares outstanding

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

250,000,000

250,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

16,575,209

144,976,757

99,784,982

'

165,856

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

16,575,209

144,976,757

99,784,982

'

165,856

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued during the period

'

'

'

'

'

2,631,579

3,953,489

'

'

'

'

'

'

'

'

'

29,411,765

13,750,000

Share price (in dollars per share)

'

'

'

'

'

'

$2.15

'

'

'

'

'

'

'

'

'

$1.70

$2.40

Share price to underwritters (in dollars per share)

'

'

'

'

'

$0.38

'

'

'

'

'

'

'

'

'

'

$1.58

$2.23

Number of shares issued during the period,value

'

$78,650,353

$7,895,485

$1,707,000

'

$1,000,000

$7,895,485

'

'

'

'

'

'

'

'

'

$45,400,000

$30,200,000

Additional period for purchase share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

Total Additional common stock issued under shelf registration statement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,411,765

'

'

Additional common stock issued under shelf registration statement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,954,587

'

'

'

Additional common stock issued under shelf registration statement,value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,100,000

'

'

'

Numbers of options to purchase shares of common stock exercised for cash

'

'

1,691,393

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options to purchase shares of common stock, value

'

30,910

191,000

17,250

'

'

'

'

'

17,250

'

'

'

'

'

'

'

'

Numbers of options to purchase shares of common stock, cashless exercise

'

'

240,395

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued in exercise of warrants

'

'

3,102,000

'

'

'

'

'

3,102,000

'

'

'

'

'

'

'

'

'

Amount of shares issued in exercise of warrants

'

'

'

'

'

'

'

8,145,486

8,145,486

'

'

'

'

'

'

'

'

'

Value of debt converted to shares

'

'

-6,716,504

'

'

'

'

'

1,054,647

'

'

100,000

'

849,137

'

'

'

'

Numbers of shares converted for debt

'

'

'

'

'

'

'

'

2,775,415

'

1,415,136

266,822

20,266,822

'

'

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

'

'

$0.38

'

'

$0.38

'

'

'

'

'

'

Transaction cash fees

'

'

'

'

'

'

552,500

'

'

'

'

'

'

'

'

'

'

'

Legal fees and expenses paid

'

'

'

'

'

'

52,016

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price of common stock sold

'

'

'

'

'

'

$8,500,001

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio

'1 for 100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_Details_Na1

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 13, 2012

Nov. 13, 2012

Nov. 13, 2012

31-May-13

Jun. 30, 2013

11-May-13

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 29, 2012

Mar. 31, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Jun. 19, 2012

Dec. 31, 2012

Jun. 19, 2012

Jun. 19, 2012

Jun. 30, 2012

Dec. 31, 2011

Dec. 31, 2011

Oct. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 13, 2012

Jan. 31, 2013

Dec. 31, 2013

Feb. 29, 2012

Feb. 24, 2012

Jun. 30, 2011

Nov. 13, 2012

Mar. 31, 2011

Mar. 31, 2011

Mar. 31, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mr. Finizio

Mr. Milligan

Reich Family Limited LP

Sancilio & Company Warrants

Sancilio & Company Warrants 1st Installments

Sancilio & Company Warrants 1st Installments

Sancilio & Company Warrants 2nd Installments

Sancilio & Company Warrants 2nd Installments

Sancilio & Company Warrants 3rd Installments

Modification Warrants

Warrants Issued to Unaffiliated Individuals

Warrants Issued to Unaffiliated Entity

Warrants Issued to Unaffiliated Entity

Warrants Issued to Unaffiliated Entity

June 2012 Notes/Warrants

June 2012 Notes/Warrants

June 2012 Notes/Warrants 1st Issue

June 2012 Notes/Warrants 2nd Issue

Warrants Issued to Unaffiliated Individuals

Warrants Issued to Unrelated Individual for Consulting Services

Warrants Issued to Unrelated Individual for Consulting Services

Warrants Issued Officers

Warrants Issued Officers

Warrants Issued Officers

Warrants Issued Officers

Warrants Issued to Unrelated Entity for Consulting Services

Warrants Issued to Unrelated Entity for Consulting Services

Vested non forfeitable VitaMed Warrants

Vested non forfeitable VitaMed Warrants

Vested non forfeitable VitaMed Warrants

Vested non forfeitable VitaMed Warrants

Vested non forfeitable VitaMed Warrants

Vested non forfeitable VitaMed Warrants

Multiple Advance Revolving Credit Note (Plato Warrant)

Multiple Advance Revolving Credit Note (Plato Warrant)

February 2012 Notes/ Warrants

February 2012 Notes/ Warrants

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

Minimum

Maximum

Weighted Average

Number

Number

Number

Mr. Finizio

Mr. Milligan

Reich Family Limited LP

Warrants:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

$14,293,499

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average contractual remaining life

'3 years 10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per share)

'

'

'

'

'

'

2.01

'

'

'

'

'

0.38

'

2.57

'

'

'

'

2

3

'

'

'

0.38

'

'

'

0.38

0.38

0.41

0.24

'

'

0.41

'

3.2

'

0.38

'

0.41

'

'

'

'

'

0.24

3.2

1.79

Unamortized costs of warrants

1,599,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares purchased

'

'

'

'

'

'

850,000

'

283,333

283,333

'

283,334

3,314,700

31,000

1,300,000

'

'

7,000,000

'

6,000,000

1,000,000

1,500

500

500

600,000

7,158

36,284

36,284

184,211

184,211

200,000

'

93,969

'

200,000

'

1,250,000

'

5,685,300

3,314,700

613,718

'

'

'

'

'

'

'

'

Expiration date of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Jan-19

'

'

'

'

'

'

'

'

'

'

'

'

Vesting date of warrants

'

'

'

'

'

'

'

'

30-Jun-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants

'

'

'

'

'

'

'

405,066

'

462,196

'

'

6,124,873

'

1,532,228

'

'

9,424,982

'

'

'

'

338

338

133,045

'

'

'

25,980

25,980

12,548

'

'

'

12,548

'

1,711,956

'

10,505,247

'

30,993

'

'

'

'

'

'

'

'

Expected term

'

'

'

'

'

'

'

'5 years

'

'5 years

'

'

'5 years

'5 years

'5 years

'

'

'5 years

'

'

'

'5 years

'10 years

'

'10 years

'

'

'

'5 years

'

'5 years

'

'10 years

'

'

'

'6 years

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

Volatility rate

'

'

'

'

'

'

'

45.89%

'

45.84%

'

'

44.50%

44.81%

44.71%

'

'

44.64%

'

'

'

44.78%

51.83%

'

45.94%

'

'

'

41.04%

'

39.44%

'

47.89%

'

'

'

44.29%

'

44.50%

'

'

'

'

'

'

'

'

'

'

Risk free rate

'

'

'

'

'

'

'

45.89%

'

1.41%

'

'

89.00%

1.04%

0.74%

'

'

0.75%

'

'

'

0.72%

0.91%

'

2.23%

'

'

'

1.08%

'

1.56%

'

3.48%

'

'

'

0.88%

'

89.00%

'

'

'

'

'

'

'

'

'

'

Dividend yield

'

'

'

'

'

'

'

0.00%

'

0.00%

'

'

0.00%

0.00%

0.00%

'

'

0.00%

'

'

'

0.00%

0.00%

'

0.00%

'

'

'

0.00%

'

0.00%

'

0.00%

'

'

'

0.00%

'

0.00%

'

0.00%

'

'

'

'

'

'

'

'

Amortization deferred financing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,532,228

'

'

547,210

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

260,022

'

'

28,719

'

'

'

'

'

'

'

'

Deferred financing costs

260,022

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,451,934

'

'

'

'

'

'

'

'

'

'

'

Number of shares purchased forfeit

'

'

'

'

'

'

833,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Valuation method of warrants

'

'

'

'

'

'

'

'Black-Scholes Model

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash compensation recongised

'

'

'

'

'

'

'

405,066

'

'

77,034

'

'

'

'

360,528

218,045

'

'

'

'

'

'

15

'

7,158

36,284

36,284

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid expense-short term

'

'

'

'

'

'

'

'

'

'

154,068

'

'

'

360,528

360,528

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid expense-long term

'

'

'

'

'

'

'

'

'

'

308,128

'

'

'

593,127

593,127

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

323

323

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants by relative fair value calculation method

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,649,890

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining amortization deferred financing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,102,680

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

859,647

'

'

'

'

'

'

'

'

'

'

Number of unaffiliated individuals

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Professional fees

'

'

'

'

'

'

'

'

'

'

'

'

'

29,736

'

'

'

'

'

'

'

1,656

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of vesting period of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44).

'

'

'

'

'

'

'Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement covering period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,980

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization research and development expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,548

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

13,551,263

4,492,362

107,241

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

6,936

5,612

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

Minimum volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39.13%

'

'

'

'

'

'

'

'

Maximum volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39.15%

'

'

'

'

'

'

'

'

Minimum risk free rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.38%

'

'

'

'

'

'

'

'

Maximum risk free rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.65%

'

'

'

'

'

'

'

'

Line of credit

'

'

'

179,000

179,000

179,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

100,000

'

'

'

'

'

299,220

300,000

100,000

100,000

100,000

'

'

'

Warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

613,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

562,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan guaranty costs

$2,944

$45,036

$38,159

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,944

$45,036

$38,159

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_Details_Na2

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numbers of options oustanding	'	'	'
Share-based compensation expense	$3,207,238	$1,868,345	$190,513
Total unrecognized estimated compensation expense	3,921,000	4,391,000	244,000
Recognized weighted-average period	'1 year 3 months 18 days	'	'
Minimum	'	'	'
Option exercise prices (in dollars per shares)	$0.10	'	'
Maximum	'	'	'
Option exercise prices (in dollars per shares)	$4.67	'	'
2009 Long Term Incentive Compensation Plan	'	'	'
Description of plan	'To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards.	'	'
Number of shares authorized for issuance	25,000,000	'	'
Number of shares issued	13,632,742	'	'
Non Qualified 2012 Stock Incentive Plan	'	'	'
Description of plan	'Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.	'	'
Number of shares authorized for issuance	10,000,000	'	'
Number of shares issued	2,650,000	'	'
Non Qualified 2012 Stock Incentive Plan | Restricted stock unit	'	'	'
Share-based compensation expense	53,428	'	'
Number of shares purchased	50,000	'	'
Vesting date	'2014-04-01	'	'
Fair value	$233,500	'	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (Warrants, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrants	'	'	'
Number of shares under warrant	'	'	'
Warrants outstanding, beginning	12,193,499	3,057,627	'
Warrants issued	2,100,000	17,332,500	3,057,627
Warrants exercised	'	-8,145,486	'
Warrants expired	'	'	'
Warrants cancelled	'	-51,142	'
Warrants outstanding, ending	14,293,499	12,193,499	3,057,627
Vested and Exercisable	13,764,710	'	'
Weighted Average Exercise Price	'	'	'
Warrants outstanding, beginning	1.63	0.36	'
Warrants issued	2.72	1.26	0.36
Warrants exercised	'	0.38	'
Warrants cancelled	'	0.24	'
Warrants outstanding, ending	1.79	1.63	0.36
Vested and Exercisable	1.81	'	'
Weighted Average Remaining Contractual Life	'	'	'
Warrants outstanding, beginning	'	'7 years 10 months 24 days	'
Warrants issued	'4 years 9 months 18 days	'4 years 3 months 18 days	'7 years 10 months 24 days
Warrants outstanding, ending	'3 years 10 months 24 days	'	'7 years 10 months 24 days
Vested and Exercisable	'3 years 10 months 24 days	'	'
Aggregate Intrinsic Value	'	'	'
Warrants outstanding, beginning	$17,971,994	$3,483,691	'
Warrants issued	5,232,500	31,891,150	3,483,691
Warrants outstanding, ending	48,932,777	17,971,994	3,483,691
Vested and Exercisable	$46,840,559	'	'

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (Warrants, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]	'	'	'
Weighted average fair value	$2.83	$2.05	$0.16
Term (in years)	'	'5 years	'
Dividend yield	0.00%	0.00%	0.00%
Minimum	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Risk-free interest rate	0.88%	0.72%	0.91%
Volatility	44.29%	44.64%	39.13%
Term (in years)	'5 years	'	'5 years
Maximum	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Risk-free interest rate	1.12%	1.04%	3.48%
Volatility	45.89%	44.81%	51.83%
Term (in years)	'6 years	'	'10 years

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2) (Stock Options)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%
Minimum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	0.65%	0.61%	0.91%
Expected Volatility	33.35%	40.77%	37.92%
Expected term	'5 years	'5 years	'5 years 6 months
Maximum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	1.71%	2.23%	2.54%
Expected Volatility	45.76%	46.01%	40.48%
Expected term	'6 years 3 months	'6 years 3 months	'6 years 3 months

STOCKHOLDERS_EQUITY_Details_3

STOCKHOLDERS' EQUITY (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Number Options	'	'	'
Options outstanding, ending	'	'	'
Stock Options	'	'	'
Number Options	'	'	'
Options outstanding, beginning	13,733,488	10,590,161	'
Options Granted	2,583,677	5,121,250	10,682,218	[1]
Options Exercised	-75,423	-1,931,788	-92,057
Options Expired	-250	'	'
Options Cancelled	-608,750	-46,135	'
Options outstanding, ending	15,632,742	13,733,488	10,590,161
Vested and exercisable	11,282,627	'	'
Weighted Average Exercise Price	'	'	'
Options outstanding, beginning	$1.16	$0.16	'
Granted	$3.31	$2.80	$0.16	[1]
Exercised	'	$0.13	$0.19
Options outstanding, ending	$1.44	$1.16	$0.16
Vested and exercisable	$0.80	'	'
Weighted Average Remaining Contractual Life	'	'	'
Options outstanding, beginning	'7 years 8 months 12 days	'7 years 7 months 6 days	'
Granted	'9 years 9 months 18 days	'9 years 8 months 12 days	'7 years 7 months 6 days	[1]
Options outstanding, ending	'7 years 2 months 12 days	'7 years 8 months 12 days	'7 years 7 months 6 days
Vested and exercisable	'6 years 6 months	'	'
Aggregate Intrinsic Value	'	'	'
Options outstanding, beginning	$26,804,117	$14,067,649	'
Granted	$4,920,981	$1,737,530	$14,188,484	[1]
Options outstanding, ending	58,878,132	26,804,117	14,067,649
Vested and exercisable	$48,321,930	'	'
[1]	This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.

INCOME_TAXES_Details_Narrative

INCOME TAXES (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Federal	'	'	'
Net operating loss carryforwards	$37,000,000	'	'
State	'	'	'
Net operating loss carryforwards	$35,000,000	$35,000,000	$35,000,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Income Tax Assets:	'	'	'
Net operating losses	$14,773,537	$5,920,861	$748,404
R&D Credit	547,511	186,346	'
Total deferred income tax asset	15,321,048	6,107,207	748,404
Valuation allowance	-15,321,048	-6,107,207	-748,404
Deferred Income Tax Assets, net	$0	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal statutory tax rate	35.00%	35.00%	35.00%
State tax rate, net of federal tax benefit	5.80%	5.50%	0.00%
Adjustment in valuation allowances	-32.40%	-18.20%	-5.80%
Permanent and other differences	-8.40%	-22.30%	-29.20%
Provision (Benefit) for Income Taxes	0.00%	0.00%	0.00%

RELATED_PARTIES_Details_Narrat

RELATED PARTIES (Details Narrative) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 04, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2012

Nov. 13, 2012

Nov. 13, 2012

Nov. 13, 2012

Jun. 30, 2012

Oct. 30, 2011

Jun. 30, 2011

Nov. 13, 2012

Mar. 31, 2011

Oct. 04, 2012

Jun. 30, 2012

Mar. 31, 2011

Mar. 31, 2011

Mar. 31, 2011

Dec. 31, 2011

Jun. 30, 2012

Oct. 04, 2012

Agreement and Plan of Merger with VitaMed

Brian Bernick

Brian Bernick

Brian Bernick

Stock Purchase Agreement With Pernix Therapeutics LLC

Stock Purchase Agreement With Pernix Therapeutics LLC

Stock Purchase Agreement With Pernix Therapeutics LLC

Non-affiliated third party

Mr. Finizio

Mr. Milligan

Reich Family Limited LP

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

VitaMed Promissory Notes

Notes Issued to Mr. Finizio And Mr. Milligan

Notes Issued to Mr. Finizio

Notes Issued to Mr. Milligan

Brian Bernick

Brian Bernick

Mr. Finizio

Mr. Milligan

Reich Family Limited LP

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit

'

'

'

'

'

'

'

'

'

'

'

$179,000

$179,000

$179,000

'

'

'

$299,220

$300,000

'

'

$100,000

$100,000

$100,000

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

100,000

'

'

Aggregate remaining principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

Repayments of notes payable

4,691,847

1,850,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000

200,000

'

'

100,000

'

'

'

'

'

'

'

Acrued interest paid

212,853

17,253

696

'

'

'

'

'

'

'

'

'

'

'

2,160

'

'

'

'

5,341

'

'

'

'

'

888

1,519

Shares reserved for future isssuance

'

'

'

70,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of lock in period

'

'

'

'Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transaction amounts

'

'

'

'

0

2,632

20,669

0

404,000

19,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Receivables outstanding

'

'

'

'

0

1,272

0

46,000

308,000

19,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Legal fee reimbursement

'

'

'

'

'

'

'

$249,981

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares purchased

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

613,718

'

'

'

'

'

'

'

'

'

'

BUSINESS_CONCENTRATIONS_Detail

BUSINESS CONCENTRATIONS (Details Narrative)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Supplier Concentration Risk	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk	98.00%	76.00%	95.00%
Revenue - Prescription dietary	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk	79.00%	63.00%	42.00%
Net Revenue	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk	64.00%	28.00%	'
Deferred revenue	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk	97.00%	98.00%	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	6 Months Ended		12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Non-cancelable operating lease term	'	'	'63 months	'	'
Monthly Base rent of leases	'	'	$30,149	'	'
Future minimum lease payments	1,766,252	'	1,766,252	'	'
Rental Expense	180,894	60,168	'	106,315	122,752
Rental Income	$32,963	'	'	'	'

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Future minimum rental payments	'
2014	$316,039
2015	371,240
2016	382,377
2017	393,848
2018	302,748
Total minimum lease payments	1,766,252
Noncancelable sub-lease income	-38,956
Net minimum lease payments	$1,727,296

SELECTED_QUARTERLY_FINANCIAL_D2

SELECTED QUARTERLY FINANCIAL DATA (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$2,863,000	$2,295,000	$2,081,000	$1,537,000	$1,241,000	$1,036,000	$819,000	$722,000	$8,775,598	$3,818,013	$2,088,177
Gross profit	2,396,000	1,646,000	1,617,000	1,157,000	908,000	729,000	447,000	386,000	6,816,001	2,469,900	1,141,065
Net loss	($8,361,000)	($7,673,000)	($6,009,000)	($6,376,000)	($5,727,000)	($4,253,000)	($11,850,000)	($13,290,000)	($28,419,313)	($35,120,235)	($12,913,365)
Loss per common share, basic and diluted (in dollars per shares)	($0.06)	($0.06)	($0.05)	($0.06)	($0.06)	($0.04)	($0.14)	($0.16)	($0.22)	($0.38)	($0.21)

SUBSEQUENT_EVENTS_Details_Narr

SUBSEQUENT EVENTS (Details Narrative) (Stock Options)	12 Months Ended				0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		Jan. 06, 2014
					Subsequent Event
Options Granted	2,583,677	5,121,250	10,682,218	[1]	390,000
Exercise period	'	'	'		'10 years
Date awards vest	'	'	'		'2014-12-31
[1]	This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.